1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
|
2
|
Cancer Research UK: UK Pancreatic Cancer
Statistics: http://info.cancerresearchuk.org/cancerstats/types/pancreas
Accessed October 24, 2006.
|
3
|
Le Scodan R, Mornex F, Girard N, et al:
Preoperative chemoradiation in potentially resectable pancreatic
adenocarcinoma: feasibility, treatment effect evaluation and
prognostic factors, analysis of the SFRO-FFCD 9704 trial and
literature review. Ann Oncol. 20:1387–1396. 2009.
|
4
|
Holick MF: Vitamin D deficiency. N Engl J
Med. 357:266–281. 2007. View Article : Google Scholar
|
5
|
Nagpal S, Na S and Rathnachalam R:
Noncalcemic actions of vitamin D receptor ligands. Endocr Rev.
26:662–687. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Muszkat P, Camargo MB, Griz LH and
Lazaretti-Castro M: Evidence-based non-skeletal actions of vitamin
D. Arq Bras Endocrinol Metabol. 54:110–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Florentin M, Elisaf MS, Mikhailidis DP and
Liberopoulos EN: Vitamin D and metabolic syndrome: is there a link?
Curr Pharm Des. 16:3417–3434. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Giovannucci E, Liu Y, Rimm EB, Hollis BW,
Fuchs CS, Stampfer MJ and Willett WC: Prospective study of
predictors of vitamin D status and cancer incidence and mortality
in men. J Natl Cancer Inst. 98:451–459. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Mahmoudi T, Mohebbi SR, Pourhoseingholi
MA, et al: Vitamin D receptor gene ApaI polymorphism is associated
with susceptibility to colorectal cancer. Dig Dis Sci.
55:2008–2013. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kizildag S, Gulsu E, Bagci O, Yuksel E and
Canda T: Vitamin D receptor gene polymorphisms and male breast
cancer risk in Turkish population. J BUON. 16:640–645.
2011.PubMed/NCBI
|
11
|
Arjumand W, Ahmad ST, Seth A, et al:
Vitamin D receptor FokI and BsmI gene polymorphism and its
association with grade and stage of renal cell carcinoma in North
Indian population. Tumor Biol. 33:23–31. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Shui IM, Mucci LA, Kraft P, Tamimi RM,
Lindstrom S, et al: Vitamin D-related genetic variation, plasma
vitamin D, and risk of lethal prostate cancer: a prospective nested
case-control study. J Natl Cancer Inst. 104:690–699. 2012.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Harries LW, Stubbins MJ, Forman D, Howard
GC and Wolf CR: Identification of genetic polymorphisms at the
glutathione S-transferase Pi locus and association with
susceptibility to bladder, testicular and prostate cancer.
Carcinogenesis. 18:641–644. 1997. View Article : Google Scholar : PubMed/NCBI
|
14
|
Ries LAG, Eisner MP, Kosary CL, et al:
National Cancer Institute: SEER cancer statistics review,
1975–2002. http://seer.cancer.gov/csr/1975_2002/.
Accessed September 19, 2007.
|
15
|
Vogt DP: Pancreatic cancer: a current
overview. Curr Surg. 57:214–220. 2000. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wong A and Chan A: Survival benefit of
tamoxifen therapy in adenocarcinoma of pancreas. Cancer.
71:2200–2203. 1993. View Article : Google Scholar : PubMed/NCBI
|
17
|
Mantell DJ, Owens PE, Bundred NJ, Mawer EB
and Canfield AE: 1 α,25-dihydroxyvitamin D(3) inhibits angiogenesis
in vitro and in vivo. Circ Res. 87:214–220. 2000.
|
18
|
Zeeb H and Greinert R: The role of vitamin
D in cancer prevention: does UV protection conflict with the need
to raise low levels of vitamin D? Dtsch Arztebl Int. 107:638–643.
2010.PubMed/NCBI
|
19
|
International Agency for Research on
Cancer: IARC Working Group Reports: Vitamin D and Cancer, 2008.
http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk5/index.php.
Accessed November 24, 2008.
|
20
|
Colston KW, James SY, Ofori-Kuragu EA,
Binderup L and Grant AG: Vitamin D receptors and anti-proliferative
effects of vitamin D derivatives in human pancreatic carcinoma
cells in vivo and in vitro. Br J Cancer. 76:1017–1020. 1997.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Albrechtsson E, Jonsson T, Möller S,
Höglund M, et al: Vitamin D receptor is expressed in pancreatic
cancer cells and a vitamin D3 analogue decreases cell number.
Pancreatology. 3:41–46. 2003. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ogunkolade BW, Boucher BJ, Prahl JM,
Bustin SA, Burrin JM, Noonan K, et al: Vitamin D receptor (VDR)
mRNA and VDR protein levels in relation to vitamin D status,
insulin secretory capacity, and VDR genotype in Bangladeshi Asians.
Diabetes. 51:2294–2300. 2002. View Article : Google Scholar : PubMed/NCBI
|
23
|
Cross HS: Extrarenal vitamin D hydroxylase
expression and activity in normal and malignant cells: modification
of expression by epigenetic mechanisms and dietary substances. Nutr
Rev. 65:S108–S112. 2007. View Article : Google Scholar : PubMed/NCBI
|
24
|
Chen TC and Kittaka A: Novel vitamin d
analogs for prostate cancer therapy. ISRN Urol.
2011:3014902011.PubMed/NCBI
|
25
|
Köstner K, Denzer N, Müller CS, Klein R,
Tilgen W and Reichrath J: The relevance of vitamin D receptor (VDR)
gene polymorphisms for cancer: a review of the literature.
Anticancer Res. 29:3511–3536. 2009.PubMed/NCBI
|
26
|
Raimondi S, Johansson H, Maisonneuve P and
Gandini S: Review and meta-analysis on vitamin D receptor
polymorphisms and cancer risk. Carcinogenesis. 30:1170–1180. 2009.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Jurutka PW, Whitfield GK, Hsieh JC,
Thompson PD, Haussler CA and Haussler MR: Molecular nature of the
vitamin D receptor and its role in regulation of gene expression.
Rev Endocr Metab Disord. 2:203–216. 2001. View Article : Google Scholar : PubMed/NCBI
|
28
|
Uitterlinden AG, Fang Y, Van Meurs JB,
Pols HA and Van Leeuwen JP: Genetics and biology of vitamin D
receptor polymorphisms. Gene. 338:143–156. 2004. View Article : Google Scholar : PubMed/NCBI
|
29
|
Makariou S, Liberopoulos EN, Elisaf M and
Challa A: Novel roles of vitamin D in disease: what is new in 2011?
Eur J Intern Med. 22:355–362. 2011. View Article : Google Scholar : PubMed/NCBI
|